Cardiac and neurologic disease – a leading cause of coronary disease, stroke
Pulmonary disease – chronic obstructive pulmonary disease (includes chronic bronchitis and emphysema), asthma, respiratory infections and an overall decrease in pulmonary function
Pregnancy – difficulty in conceiving, intrauterine growth retardation and low birth weight
Second-hand smoke (a confirmed human carcinogen) is implicated in pulmonary disease, lung cancer and coronary artery disease in non-smokers
Monitoring for tobacco use is helpful in the following situations:
Compliance with requirements in smoking cessation programs
Candidates for orthopedic surgery (particularly spinal fusion), pulmonary therapy and organ transplant programs
Identification of tobacco-using patients on drug therapy for a variety of health problems
Women on high-level estrogen therapy (increased risk for stroke and heart attack)
Child custody cases when parent needs to comply with smoking cessation program as condition of visitation rights
Experimental nicotine therapy in cognitive degeneration disorders, e.g., Alzheimer disease, Parkinson disease and attention deficit/hyperactivity disorder (ADHD)
Laboratory Testing
Urine testing recommended over serum/plasma testing
Nicotine and related compounds are detected over a longer period of time in urine and can differentiate:
Active user
Abstinent user of more than 2 weeks
Passive exposure
Unexposed non-tobacco user
Anabasine in urine indicates that donor is actively using a tobacco product; anabasine does not occur in nicotine replacement products
Serum plasma testing is required when a valid urine specimen cannot be obtained (anuretic or dialysis patient)
Serum/plasma cannot distinguish between last 3 categories after 2 weeks' abstinence
Detect nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine and anabasine, in urine
Monitor tobacco use in compliance-related and health-related situations
Identify presence of anabasine, not detectable in serum/plasma, which definitively identifies non-compliant patient in smoking-cessation program who is on nicotine replacement therapy
Distinguish between categories of tobacco exposure and/or use
Detects nicotine, cotinine, and trans-3'-hydroxycotinine in serum
Monitor tobacco use in compliance-related and health-related situations
Order for patients when a valid urine specimen cannot be obtained (e.g., anuretic or dialysis patient)
Cannot differentiate between active smoking and nicotine replacement therapy
Additional Information
Nicotine & Metabolites, Urine allows categorization of donors as unexposed non-tobacco users, passively exposed, abstinent users (greater than 2 weeks), and active users.
General References
Moyer TP, Charlson JR, Enger RJ, Dale LC, Ebbert JO, Schroeder DR, Hurt RD.Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles.Clin Chem. 2002;48(9):1460-1471. (Link to PubMed)
Tutka P, Mosiewicz J, Wielosz M.Pharmacokinetics and metabolism of nicotine.Pharmacol Rep. 2005;57(2):143-153. (Link to PubMed)
Yildiz D.Nicotine, its metabolism and an overview of its biological effects.Toxicon. 2004;43(6):619-632. (Link to PubMed)
Reviewed by
McMillin, Gwen, Ph.D. Medical Director of Clinical Drug Abuse Testing, Clinical Toxicology and Trace Elements, Co-Medical Director for Pharmacogenomics at ARUP Laboratories; Assistant Professor, Pathology, University of Utah
Comprehensive Review: November 2007
Last Update: November 2007